The first Harvard Institute of Translational Immunology (HITI)/Helmsley Trust Pilot Grant RFA – focused on type 1 diabetes – will be available on November 18, 2010
Posted November 10, 2010
On November 18, 2010, the Harvard Institute of Translational Immunology (HITI) and the Leona M. and Harry B. Helmsley Charitable Trust will release a Request for Applications (RFA) focused on type 1 diabetes (T1D). This new RFA is inspired by the winners of the Harvard Catalyst/InnoCentive Ideation Challenge, “What do we not know about type 1 diabetes.”
Any investigator with a Harvard faculty appointment, regardless of degree or institutional affiliation, is eligible to apply for these one-year grants. Award amounts will range from $50,000 to $200,000.
Complete information on this opportunity, including the full RFA, will be available on the Harvard Catalyst website on November 18. Investigators are asked to wait until the full RFA is available before making any inquiries regarding the specific research topics supported by the grant program.
HITI is a newly-established collaborative effort – recently announced by HMS Dean Jeffrey Flier, MD – which will bring together basic, translational, and clinical investigators from across the Harvard community to develop interdisciplinary approaches for elucidating mechanisms of immune-mediated diseases.
Established in 1999, the Leona M. and Harry B. Helmsley Charitable Trust continues Mr. and Mrs. Helmsley’s remarkable philanthropic legacy. The Trust supports a broad spectrum of healthcare and medical research-based programs, including innovative and collaborative funding for research on T1D.